TALAPRO-3 研究中来自 @AzadOncology 在 #ESMO26 的 ctDNA 肿瘤分数 🧬 在 HRR 缺陷的 mCSPC 中，基线 ctDNA 阳性（TF ≥1%）在两组中均对 rPFS 具有预后意义。第 5 周也很重要：82% 的 ctDNA 阳性患者在 TALA + ENZA 组清除，而 PBO + ENZA 组为 68%，且清除与更长的 rPFS 相关（HR 0.36 对比持续 ctDNA 阳性）。早期治疗中 ctDNA 可能成为风险分层和监测的真实工具。接下来要看它是否在 PSA 之外增加价值。#MRD #ctDNA #ProstateCancer
256 浏览 · 5 赞 · 5 转发 · 0 回复
Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta
https://esmocongress.esmo.orgPlasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)
https://esmocongress.esmo.orgCharacterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study
https://esmocongress.esmo.orgClinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors
https://esmocongress.esmo.orgctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgUltrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study
https://esmocongress.esmo.org来源：Alan Tan · x.com